{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:47:37Z","timestamp":1785160057022,"version":"3.55.0"},"reference-count":41,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["15K09432"],"award-info":[{"award-number":["15K09432"]}]},{"name":"JSPS KAKENHI","award":["22K08654"],"award-info":[{"award-number":["22K08654"]}]},{"name":"JSPS KAKENHI","award":["21K10474"],"award-info":[{"award-number":["21K10474"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We comparatively analyzed the clinical features of this combination and each individual ICI-induced endocrinopathy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reported 3 cases that we encountered and reviewed previously reported cases of patients with combined hypophysitis and T1DM due to ICIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Anti-programmed cell death-1 (anti-PD-1) antibodies were prescribed to all 3 cases. The duration from ICI initiation to the onset of endocrine disease was 12 to 48 weeks. Several human leukocyte antigen (HLA) haplotypes that have disease susceptibility to hypophysitis were detected in all 3 patients. With the 17 previously reported cases, combined endocrinopathies were more common in men (85%). The onset age was in the 60s for both combined and single endocrinopathies. Anti-PD-1 antibodies were used in most of the cases (90%). The time from ICI initiation to the onset of endocrinopathies was 24 (8-76) weeks for hypophysitis and 32 (8-76) weeks for T1DM in patients with combined endocrinopathies, which was not significantly different from that for each single endocrinopathy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We presented 3 cases of patients with combined endocrinopathies of hypophysitis and T1DM that may have been caused by anti-PD-1 antibodies. There was no difference in the time from ICI initiation to the onset of endocrinopathies between combined and single endocrinopathies. Further case accumulation and pathogenic investigations are required.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvad002","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T04:44:46Z","timestamp":1673153086000},"source":"Crossref","is-referenced-by-count":7,"title":["Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors"],"prefix":"10.1210","volume":"7","author":[{"given":"Yasunori","family":"Fujita","sequence":"first","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumika","family":"Kamitani","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Nara Medical University , Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-653X","authenticated-orcid":false,"given":"Hidenori","family":"Fukuoka","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Hospital , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Hirota","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Hospital , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naho","family":"Goda","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Hospital , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Okada","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Hospital , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuiko","family":"Inaba","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Hospital , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Nara Medical University , Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Kurematsu","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Nara Medical University , Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9004-9857","authenticated-orcid":false,"given":"Keitaro","family":"Kanie","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Shichi","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Urai","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-2714","authenticated-orcid":false,"given":"Hironori","family":"Bando","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Hospital , Kobe , Japan"},{"name":"Division of Development of Advanced Therapy for Metabolic Diseases, Department of Internal Medicine, Kobe University Graduate School of Medicine , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genzo","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine , Kobe , Japan"},{"name":"Medical Center for Student Health, Kobe University , Kobe , Japan"},{"name":"Division of Biosignal Pathophysiology, Kobe University Graduate School of Medicine , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Suto","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine , Kobe , Japan"},{"name":"Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Funakoshi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine , Kobe , Japan"},{"name":"Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Kobe University Graduate School of Medicine , Kobe , Japan"},{"name":"Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Nara Medical University , Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Kobe University Graduate School of Medicine , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"issue":"4","key":"2023012017001129600_bvad002-B1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6382","key":"2023012017001129600_bvad002-B2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"3","key":"2023012017001129600_bvad002-B3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/eji.202048747","article-title":"Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur J Immunol"},{"issue":"21","key":"2023012017001129600_bvad002-B4","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"2023012017001129600_bvad002-B5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2023012017001129600_bvad002-B6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy treating immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"2","key":"2023012017001129600_bvad002-B7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"2023012017001129600_bvad002-B8","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/EJE-19-1051","article-title":"Mechanisms in endocrinology: autoimmune hypopituitarism: novel mechanistic insights","volume":"182","author":"Takahashi","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2023012017001129600_bvad002-B9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr J"},{"issue":"3","key":"2023012017001129600_bvad002-B10","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1159\/000510044","article-title":"Type 1 diabetes, ACTH deficiency, and hypothyroidism simultaneously induced by nivolumab therapy in a patient with gastric cancer: a case report","volume":"13","author":"Marshall","year":"2020","journal-title":"Case Rep Oncol"},{"issue":"4","key":"2023012017001129600_bvad002-B11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1507\/endocrj.EJ18-0328","article-title":"Fuluminant type 1 diabetes associated with isolated ACTH deficiency induced by anti-programmed cell death 1 antibody-insight into the pathogenesis of autoimmune endocrinopathy","volume":"66","author":"Okahata","year":"2019","journal-title":"Endocr J"},{"issue":"4","key":"2023012017001129600_bvad002-B12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1507\/endocrj.K10E-399","article-title":"Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes","volume":"58","author":"Saisho","year":"2011","journal-title":"Endocr J"},{"issue":"4","key":"2023012017001129600_bvad002-B13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.2040-1124.2010.00096.x","article-title":"Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes.","volume":"2","author":"Funakoshi","year":"2011","journal-title":"J Diabetes Investig"},{"issue":"6","key":"2023012017001129600_bvad002-B14","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/cen.14082","article-title":"Comparative analysis of human leucocyte antigen between idiopathic and anti-PD-1 antibody induced isolated adrenocorticotropic hormone deficiency: a pilot study","volume":"91","author":"Inaba","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"2023012017001129600_bvad002-B15","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00125-009-1539-9","article-title":"Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset","volume":"52","author":"Kawabata","year":"2009","journal-title":"Diabetologia"},{"key":"2023012017001129600_bvad002-B16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejca.2020.02.049","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","journal-title":"Eur J Cancer"},{"issue":"37","key":"2023012017001129600_bvad002-B17","doi-asserted-by":"crossref","first-page":"14034","DOI":"10.1073\/pnas.0806584105","article-title":"Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice","volume":"105","author":"Menconi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2023012017001129600_bvad002-B18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1507\/endocrj.EJ20-0371","article-title":"Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors","volume":"68","author":"Inaba","year":"2021","journal-title":"Endocr J"},{"issue":"2","key":"2023012017001129600_bvad002-B19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"2023012017001129600_bvad002-B20","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2023012017001129600_bvad002-B21","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1530\/EJE-19-0169","article-title":"Management of endocrine disease: immune check point inhibitors-induced hypophysitis","volume":"181","author":"Albarel","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023012017001129600_bvad002-B22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2023012017001129600_bvad002-B23","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023012017001129600_bvad002-B24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/js.2017-00414","article-title":"Two cases of atezolizumab-induced hypophysitis","volume":"2","author":"Kanie","year":"2017","journal-title":"J Endocr Soc"},{"issue":"5","key":"2023012017001129600_bvad002-B25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-015-2873-x","article-title":"Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma","volume":"76","author":"Yamazaki","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2023012017001129600_bvad002-B26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13256-019-2002-2","article-title":"Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature","volume":"13","author":"Ohara","year":"2019","journal-title":"J Med Case Rep"},{"issue":"6","key":"2023012017001129600_bvad002-B27","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J Endocr Soc"},{"issue":"3","key":"2023012017001129600_bvad002-B28","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2023012017001129600_bvad002-B29","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"issue":"4","key":"2023012017001129600_bvad002-B30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11102-006-0408-5","article-title":"Isolated corticotrophin deficiency","volume":"9","author":"Andrioli","year":"2006","journal-title":"Pituitary"},{"issue":"6","key":"2023012017001129600_bvad002-B31","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdi.12024","article-title":"Report of the committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012)","volume":"3","author":"Imagawa","year":"2012","journal-title":"J Diabetes Investig"},{"issue":"8","key":"2023012017001129600_bvad002-B32","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"6","key":"2023012017001129600_bvad002-B33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"11","key":"2023012017001129600_bvad002-B34","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023012017001129600_bvad002-B35","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"2023012017001129600_bvad002-B36","doi-asserted-by":"crossref","first-page":"e000779","DOI":"10.1136\/jitc-2020-000779","article-title":"Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study","volume":"8","author":"Kobayashi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"18","key":"2023012017001129600_bvad002-B37","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"2023012017001129600_bvad002-B38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer","volume":"20","author":"Grangeon","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"2023012017001129600_bvad002-B39","doi-asserted-by":"crossref","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer","volume":"7","author":"Kim","year":"2017","journal-title":"Oncoimmunology"},{"issue":"6","key":"2023012017001129600_bvad002-B40","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1034\/j.1399-0039.2000.560606.x","article-title":"Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population","volume":"56","author":"Saito","year":"2000","journal-title":"Tissue Antigens"},{"issue":"3","key":"2023012017001129600_bvad002-B41","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1210\/jc.2005-1407","article-title":"The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multicenter collaborative study in Japan","volume":"91","author":"Ikegami","year":"2006","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvad002\/48518691\/bvad002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/3\/bvad002\/48799642\/bvad002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/3\/bvad002\/48799642\/bvad002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T17:06:00Z","timestamp":1674234360000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvad002\/6972399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,1,6]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvad002","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2023,1,6]]},"article-number":"bvad002"}}